Cargando…
Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era
Coronavirus infection is a pandemic threat and the most dangerous disease of the 21(st) century. Despite the rigorous exertion of world-class researchers, there is no perfect cure for it. It has been seen in presently available studies that Paxlovid prevents the progression of diseases and reduces s...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043822/ https://www.ncbi.nlm.nih.gov/pubmed/36722557 http://dx.doi.org/10.4103/ijp.ijp_291_22 |
_version_ | 1784913235453935616 |
---|---|
author | Niraj, Niraj Mahajan, Sonia Shinde Prakash, Ajay Sarma, Phulen Medhi, Bikash |
author_facet | Niraj, Niraj Mahajan, Sonia Shinde Prakash, Ajay Sarma, Phulen Medhi, Bikash |
author_sort | Niraj, Niraj |
collection | PubMed |
description | Coronavirus infection is a pandemic threat and the most dangerous disease of the 21(st) century. Despite the rigorous exertion of world-class researchers, there is no perfect cure for it. It has been seen in presently available studies that Paxlovid prevents the progression of diseases and reduces severity in patients tremendously who are at high risk of hospitalization and death. It is a safe oral antiviral drug and has the potential to treat infections from multiple corona variants including omicron which affects humans. Paxlovid is comparatively less expensive than other available effective medicines. Consequently, it reduces hospitalization and death and helps to plummet the economic burden on patients and the health-care system globally. This medicine is still under investigation, and numerous clinical trials are still underway. Its potential side effects are minor and well tolerated by research study participants. Studies show its benefits outweigh the risk, and it is an effective and good alternative for the treatment of coronavirus disease. |
format | Online Article Text |
id | pubmed-10043822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-100438222023-03-29 Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era Niraj, Niraj Mahajan, Sonia Shinde Prakash, Ajay Sarma, Phulen Medhi, Bikash Indian J Pharmacol Short Communication Coronavirus infection is a pandemic threat and the most dangerous disease of the 21(st) century. Despite the rigorous exertion of world-class researchers, there is no perfect cure for it. It has been seen in presently available studies that Paxlovid prevents the progression of diseases and reduces severity in patients tremendously who are at high risk of hospitalization and death. It is a safe oral antiviral drug and has the potential to treat infections from multiple corona variants including omicron which affects humans. Paxlovid is comparatively less expensive than other available effective medicines. Consequently, it reduces hospitalization and death and helps to plummet the economic burden on patients and the health-care system globally. This medicine is still under investigation, and numerous clinical trials are still underway. Its potential side effects are minor and well tolerated by research study participants. Studies show its benefits outweigh the risk, and it is an effective and good alternative for the treatment of coronavirus disease. Wolters Kluwer - Medknow 2022 2023-01-31 /pmc/articles/PMC10043822/ /pubmed/36722557 http://dx.doi.org/10.4103/ijp.ijp_291_22 Text en Copyright: © 2023 Indian Journal of Pharmacology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Short Communication Niraj, Niraj Mahajan, Sonia Shinde Prakash, Ajay Sarma, Phulen Medhi, Bikash Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era |
title | Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era |
title_full | Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era |
title_fullStr | Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era |
title_full_unstemmed | Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era |
title_short | Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era |
title_sort | paxlovid: a promising drug for the challenging treatment of sars-cov-2 in the pandemic era |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043822/ https://www.ncbi.nlm.nih.gov/pubmed/36722557 http://dx.doi.org/10.4103/ijp.ijp_291_22 |
work_keys_str_mv | AT nirajniraj paxlovidapromisingdrugforthechallengingtreatmentofsarscov2inthepandemicera AT mahajansoniashinde paxlovidapromisingdrugforthechallengingtreatmentofsarscov2inthepandemicera AT prakashajay paxlovidapromisingdrugforthechallengingtreatmentofsarscov2inthepandemicera AT sarmaphulen paxlovidapromisingdrugforthechallengingtreatmentofsarscov2inthepandemicera AT medhibikash paxlovidapromisingdrugforthechallengingtreatmentofsarscov2inthepandemicera |